Ustekinumab: Phase III data

In the Phase III PHOENIX 2 trial in 1,230 patients, 67% and 76% of patients receiving 45 and 90 mg of subcutaneous ustekinumab met the primary endpoint of a PASI 75 at week 12 compared with 4% of plac...